Journal article

Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method

Felisa Reyes-Ortega, Fiona Qiu, Elena K Schneider-Futschik

ACS Pharmacology & Translational Science | AMER CHEMICAL SOC | Published : 2020


Ivacaftor-tezacaftor and ivacaftor-tezacaftor-elexacaftor are new breakthrough cystic fibrosis (CF) drug combinations that directly modulate the activity and trafficking of the defective CF transmembrane conductance regulator protein (CFTR) underlying the CF disease state. Currently, in the hospital setting, there are no therapeutic drug monitoring assays for these very expensive, albeit, life-saving drugs. A rapid and precise novel method for the quantification of ivacaftor, its metabolites, tezacaftor, and elexacaftor, in human plasma was developed and validated using multiple reaction monitoring mass spectrometry (MRM/MS). The MRM/MS analytical method was validated at a concentration rang..

View full abstract


Funding Acknowledgements

E.K.S.-F. is supported by a research grant from The University of Melbourne and the Australian National Health and Medical Research Council (NHMRC) as Biomedical Research Fellow. Portions of this work were supported by the Peter Phelan grant from the Thoracic Society of Australia and New Zealand. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Australian National Health and Medical Research Council.